Agency Information Collection Activities; Proposed Collection; Comment Request; Requirements for Collection of Data Relating to the Prevention of Medical Gas Mixups at Health Care Facilities-Survey, 122-123 [E5-8113]

Download as PDF 122 Federal Register / Vol. 71, No. 1 / Tuesday, January 3, 2006 / Notices by NIOSH. All comments in the NORA Docket will be used to help shape sector-specific and related cross-sector research agendas for the nation. These events are part of a series of public meetings which will occur in the months preceding the NORA Symposium (April 18–20, 2006 in Washington, DC). Upcoming meetings will include: Wholesale and Retail Trade; Manufacturing; Mining; Services; Regional Issues; and a summary session. Future Federal Register announcements will provide more information on these meetings. Previous meetings have discussed Transportation, Warehousing, and Utilities, and Construction. Contact Person for More Information: Sid Soderholm, Ph.D., NORA Coordinator, (202) 401–0721. Address: Comments may also be emailed to niocindocket@cdc.gov, or sent via postal mail to: Docket NIOSH–047, Robert A. Taft Laboratories (C–34), 4676 Columbia Parkway, Cincinnati, OH 45226. Stakeholders are also invited to submit comments electronically at the NORA Web page https://www.cdc.gov/ niosh/nora. Comments submitted to the Web page by others can also be viewed there. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Dated: December 27, 2005. B. Kathy Skipper, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E5–8192 Filed 12–30–05; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration rmajette on DSK29S0YB1PROD with NOTICES6 [Docket No. 2005N–0500] Agency Information Collection Activities; Proposed Collection; Comment Request; Requirements for Collection of Data Relating to the Prevention of Medical Gas Mixups at Health Care Facilities—Survey AGENCY: Food and Drug Administration, HHS. VerDate Mar<15>2010 15:46 Nov 10, 2010 Jkt 223001 ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on measures, taken by certain health care medical facilities that use medical oxygen, to prevent mixups with other gases. DATES: Submit written or electronic comments on the collection of information by March 6, 2006. ADDRESSES: Submit electronic comments on the collection of information to https://www.fda.gov/ dockets/ecomments. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, room 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Karen Nelson, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Requirements for Collection of Data Relating to the Prevention of Medical Gas Mixups at Health Care Facilities— Survey (OMB Control Number 0910– 0548)—Extension FDA has received four reports of medical gas mixups occurring during the past 7 years. These reports were received from hospitals and nursing homes and involved 7 deaths and 15 injuries to patients who were thought to be receiving medical grade oxygen, but who were actually receiving a different gas (e.g., nitrogen, argon) that had been mistakenly connected to the facility’s oxygen supply system. In 2001, FDA published guidance making recommendations to help hospitals, nursing homes, and other health care facilities avoid the tragedies that result from medical gas mixups and alerting these facilities to the hazards. This survey is intended to assess the degree of facilities’ compliance with safety measures to prevent mixups and to determine if further steps are warranted to ensure the safety of patients. FDA estimates the burden of this collection of information as follows: E:\FR\FM\03JAN1.SGM 03JAN1 123 Federal Register / Vol. 71, No. 1 / Tuesday, January 3, 2006 / Notices TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1 No. of Respondents 21 CFR Section 210 and 211 Annual Frequency per Response 285 Total Annual Responses 1 Hours per Response 285 Total Hours .25 Total 71.25 71.25 1There are no capital costs or operating and maintenance costs associated with this collection of information. Dated: December 22, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. OMB control number 0910–0116. The approval expires on December 31, 2008. A copy of the supporting statement for this information collection is available on the Internet at https://www.fda.gov/ ohrms/dockets. ADDRESSES: Comments may be submitted electronically at the TRWG Web site: https://www.cancer.gov/trwg/. SUPPLEMENTARY INFORMATION: DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: December 22, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. Food and Drug Administration [FR Doc. E5–8134 Filed 12–30–05; 8:45 am] The National Cancer Institute is committed to speeding the development of new diagnostic tests, cancer treatments, and other interventions that benefit people with cancer and people at risk for cancer. Such development relies on strong translational research collaborations between basic and clinical scientists to generate novel approaches. Currently, NCI supports a variety of projects that build this bridge between basic science and patient care. Over the next year, the Translational Research Working Group (TRWG) will review NCI’s current intramural and extramural translational research portfolio (within the scope of the TRWG mission), facilitate broad community input, invite public comment, and recommend ways to improve and integrate efforts. The ultimate goal is to accelerate progress toward improving the health of the nation and cancer patient outcomes. [FR Doc. E5–8113 Filed 12–30–05; 8:45 am] BILLING CODE 4160–01–S BILLING CODE 4160–01–S [Docket No. 2005N–0220] Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Current Good Manufacturing Practices and Related Regulations for Blood and Blood Components; and Requirements for Donor Testing, Donor Notification, and ‘‘Lookback’’ AGENCY: Food and Drug Administration, HHS. rmajette on DSK29S0YB1PROD with NOTICES6 ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ‘‘Current Good Manufacturing Practices and Related Regulations for Blood and Blood Components; and Requirements for Donor Testing, Donor Notification, and ‘Lookback’’’ has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659. SUPPLEMENTARY INFORMATION: In the Federal Register of October 24, 2005 (70 FR 61447), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned VerDate Mar<15>2010 15:46 Nov 10, 2010 Jkt 223001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Health Translational Research Working Group Public Comment Period AGENCY: National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS). ACTION: Request for public comment. SUMMARY: The Translational Research Working Group (TRWG), a broad panel including advocates, researchers from academia, industry representatives, and government officials, was established in early 2005 to evaluate the status of the National Cancer Institute’s (NCI) intramural and extramural investment in translational research in order to develop recommendations on ways to coordinate and optimally integrate activities. The TRWG is also charged with developing implementation strategies that will enable the scientific community and NCI leadership to appropriately prioritize its translational research opportunities. Recommendations will be made to the National Cancer Advisory Board by early 2007. To assist in its future planning efforts, TRWG is asking public stakeholders in the translational research enterprise for feedback on some of the key questions facing the panel and insights on how to proceed. DATES: The TRWG public comment period will run from December 20, 2005 to January 20, 2006. PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 Background Request for Comments To better understand the different viewpoints in the cancer research community, and to develop and reflect a common understanding about the challenges and opportunities in translational research, TRWG seeks input on six important areas: • Barriers to/Incentives for Translational Research. • Prioritization. • Funding. • System Organization. • Facilities/Technologies. • Manpower/Training. Dated: December 22, 2005. Ernest Hawk, Director, Office of Centers, Training and Resources, National Cancer Institute, National Institutes of Health. [FR Doc. 05–24687 Filed 12–30–05; 8:45 am] BILLING CODE 4140–01–M E:\FR\FM\03JAN1.SGM 03JAN1

Agencies

[Federal Register Volume 71, Number 1 (Tuesday, January 3, 2006)]
[Notices]
[Pages 122-123]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-8113]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2005N-0500]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Requirements for Collection of Data Relating to the 
Prevention of Medical Gas Mixups at Health Care Facilities--Survey

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on measures, taken by certain 
health care medical facilities that use medical oxygen, to prevent 
mixups with other gases.

DATES: Submit written or electronic comments on the collection of 
information by March 6, 2006.

ADDRESSES: Submit electronic comments on the collection of information 
to https://www.fda.gov/dockets/ecomments. Submit written comments on the 
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, room 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Karen Nelson, Office of Management 
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-1482.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, 
before submitting the collection to OMB for approval. To comply with 
this requirement, FDA is publishing notice of the proposed collection 
of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Requirements for Collection of Data Relating to the Prevention of 
Medical Gas Mixups at Health Care Facilities--Survey (OMB Control 
Number 0910-0548)--Extension

    FDA has received four reports of medical gas mixups occurring 
during the past 7 years. These reports were received from hospitals and 
nursing homes and involved 7 deaths and 15 injuries to patients who 
were thought to be receiving medical grade oxygen, but who were 
actually receiving a different gas (e.g., nitrogen, argon) that had 
been mistakenly connected to the facility's oxygen supply system. In 
2001, FDA published guidance making recommendations to help hospitals, 
nursing homes, and other health care facilities avoid the tragedies 
that result from medical gas mixups and alerting these facilities to 
the hazards. This survey is intended to assess the degree of 
facilities' compliance with safety measures to prevent mixups and to 
determine if further steps are warranted to ensure the safety of 
patients.
    FDA estimates the burden of this collection of information as 
follows:

[[Page 123]]



                                                     Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               No. of        Annual Frequency     Total Annual         Hours per
                     21 CFR Section                         Respondents        per Response        Responses           Response           Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
210 and 211                                                            285                  1                285                 .25               71.25
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total                                                                                                                                              71.25
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.


    Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E5-8113 Filed 12-30-05; 8:45 am]
BILLING CODE 4160-01-S
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.